These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26308278)

  • 1. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
    Lepretre S; Dartigeas C; Feugier P; Marty M; Salles G
    Leuk Lymphoma; 2016; 57(4):852-65. PubMed ID: 26308278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials.
    Vidal L; Gurion R; Ram R; Raanani P; Bairey O; Robak T; Gafter-Gvili A; Shpilberg O
    Leuk Lymphoma; 2016 Sep; 57(9):2047-57. PubMed ID: 26980554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Gordon MJ; Lewis LD; Brown JR; Danilov AV
    Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
    Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
    Begleiter A; Mowat M; Israels LG; Johnston JB
    Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
    Kimby E; Brandt L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):224-30. PubMed ID: 11441934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
    Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
    Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
    Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
    Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose chlorambucil in the treatment of lymphoid malignancies.
    Nicolle A; Proctor SJ; Summerfield GP
    Leuk Lymphoma; 2004 Feb; 45(2):271-5. PubMed ID: 15101711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
    Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
    Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
    Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
    Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of ofatumumab in the treatment of B-cell malignancies.
    Soe ZN; Allsup D
    Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
    Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
    Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
    Prescrire Int; 2005 Feb; 14(75):3-5. PubMed ID: 15747447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.